BERWYN, PA — Virpax® Pharmaceuticals, Inc. (NASDAQ: VRPX) recently announced that the cooperative research and development agreement (CRADA) with the U.S. Army Institute of Surgical Research (USAISR) to evaluate Virpax’s Probudur™, an injectable long-acting liposomal bupivacaine formulation that is injected at the wound site, has been extended to September of 2024. The USASIR is the U.S. Department of Defense’s primary laboratory for developing solutions for trauma and critical care challenges in combat casualties.
The trial, which was expected to start earlier this year, was slightly delayed due to a change in leadership at USAISR. LipoCure Rx Ltd., the manufacturer of the drug candidate, is preparing to ship the product and the trial is now expected to begin in the fourth quarter of this year.
Probudur is being developed to significantly reduce or eliminate the need for opioids after surgery in approved indications. In pre-clinical trials, Probudur has shown long duration pain control for at least 96 hours.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.